These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16452191)

  • 1. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers.
    Toyooka S; Tokumo M; Shigematsu H; Matsuo K; Asano H; Tomii K; Ichihara S; Suzuki M; Aoe M; Date H; Gazdar AF; Shimizu N
    Cancer Res; 2006 Feb; 66(3):1371-5. PubMed ID: 16452191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components.
    Kubo T; Yamamoto H; Ichimura K; Jida M; Hayashi T; Otani H; Tsukuda K; Sano Y; Kiura K; Toyooka S
    Lung Cancer; 2009 Sep; 65(3):328-32. PubMed ID: 19144441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression.
    Pulling LC; Divine KK; Klinge DM; Gilliland FD; Kang T; Schwartz AG; Bocklage TJ; Belinsky SA
    Cancer Res; 2003 Aug; 63(16):4842-8. PubMed ID: 12941804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers.
    Destro A; Bianchi P; Alloisio M; Laghi L; Di Gioia S; Malesci A; Cariboni U; Gribaudi G; Bulfamante G; Marchetti A; Bosari S; Infante M; Ravasi G; Roncalli M
    Lung Cancer; 2004 Apr; 44(1):23-32. PubMed ID: 15013580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.
    Belinsky SA; Palmisano WA; Gilliland FD; Crooks LA; Divine KK; Winters SA; Grimes MJ; Harms HJ; Tellez CS; Smith TM; Moots PP; Lechner JF; Stidley CA; Crowell RE
    Cancer Res; 2002 Apr; 62(8):2370-7. PubMed ID: 11956099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. k-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis.
    Nelson HH; Christiani DC; Wiencke JK; Mark EJ; Wain JC; Kelsey KT
    Cancer Res; 1999 Sep; 59(18):4570-3. PubMed ID: 10493509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program.
    Baryshnikova E; Destro A; Infante MV; Cavuto S; Cariboni U; Alloisio M; Ceresoli GL; Lutman R; Brambilla G; Chiesa G; Ravasi G; Roncalli M
    Clin Cancer Res; 2008 Mar; 14(6):1913-9. PubMed ID: 18347195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
    Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
    Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.
    Kim DH; Kim JS; Park JH; Lee SK; Ji YI; Kwon YM; Shim YM; Han J; Park J
    Cancer Res; 2003 Oct; 63(19):6206-11. PubMed ID: 14559805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
    Floyd HS; Jennings-Gee JE; Kock ND; Miller MS
    Mol Carcinog; 2006 Jul; 45(7):506-17. PubMed ID: 16482519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
    Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
    BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf.
    Wang Y; Zhang Z; Lubet R; You M
    Oncogene; 2005 Apr; 24(18):3042-9. PubMed ID: 15846305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
    van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
    Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers.
    Divine KK; Pulling LC; Marron-Terada PG; Liechty KC; Kang T; Schwartz AG; Bocklage TJ; Coons TA; Gilliland FD; Belinsky SA
    Int J Cancer; 2005 Apr; 114(3):400-5. PubMed ID: 15578700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.